IGC Pharma, Inc.
IGC· NYSE
Filed Nov 13, 2014 · 10-Q · 44 days after period end · 0001185185-14-003021
| Metric | Q2 2015 | Q2 2014 | Q2 2010 |
|---|---|---|---|
| Revenue | $2.12M | $1.13M | $1.68M |
| Net Income | -$887.40K | -$615.19K | -$856.26K |
| EPS Diluted | -$0.07 | -$0.09 | -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
ended Sep 30, 2014 · filed Nov 13, 2014 · 44 d after period end